Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can donated placental tissue help heal stubborn wounds?

NCT ID NCT06918561

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a wound covering made from donated human placental tissue, called NeoThelium FT, for people with chronic open wounds that have not healed for at least 4 weeks. About 132 adults will receive either standard wound care alone or standard care plus NeoThelium FT. The main goal is to see if the treatment leads to complete wound closure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NeoThelium FT (a dehydrated wound covering made from donated human placental tissue)
What this could lead to
If it works, this could provide a new treatment option to help chronic open wounds heal faster and more completely.
What could go wrong
This is an early-stage trial with no phase designation, so results are uncertain. The treatment may not prove more effective than standard care alone, and there is a risk of infection or allergic reaction.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 132 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male or Female, 18 years of age or older 2. Subject has a medical diagnosis of "other" Open wound 3. Subject has a chronic open wound present for 4 weeks or greater (documented in medical record), and less than 12 months duration if being treated with continuous SOC 4. Subject has a chronic open wound with a historical wound measurement showing less than 25% healing within 14 days prior to screening 5. Subject has a chronic open wound with screening wound measurement showing less than 25% healing within 14 days prior to randomization 6. Subject has an Open wound without infection or clinically visible exposed bone 7. Index wound is a minimum of 0.5cm2 and a maximum of 25cm2 at first treatment visit 8. Index ulcer has a maximum depth of 1cm at screening visit 1 9. The chronic open wound is treated with offloading therapy, if applicable to location, while standing, sitting, and lying down for 14 days prior to randomization 10. Adequate circulation of wounds located below the knee demonstrated by an ABI of \>0.7 and \<1.3, or TBI of \>0.6 within 30 days prior to randomization OR an arterial ultrasound noted with patent circulation and without significant stenosis 90 days prior to randomization. 11. Index ulcer is free of infection prior to randomization and during screening phase. 12. Index ulcer is free of necrotic debris prior to NeoThelium FT application 13. Female subjects of childbearing potential having a negative pregnancy test prior to randomization 14. Index ulcer is free of infection prior to randomization and during screening phase noted with the NERDS Assessment. Infection must be adequately treated and controlled prior to randomization. 15. Subject is able and willing to follow the protocol requirements 16. Subject had signed informed consent 17. If 2 or more ulcers are present, the ulcers must be separated by at least 2 cm Exclusion Criteria: 1. Subject with a wound diagnosis of diabetic foot wound, pressure wound, venous leg wound, burn wound, or alternative diagnosis other than "open wound" 2. Subject has a known life expectancy of \<1 year 3. Subject is unable to comply with protocol treatment 4. Subject has major uncontrolled medical disorders in the opinion of the investigator, such as serious cardiovascular, renal, liver, pulmonary, autoimmune, palliative care, or inherited blood disorders that may affect wound healing. 5. Subject actively being treated for malignant disease or history of malignancy or radiation therapy at the site of wound 6. Subject has comorbid conditions that may compromise subject safety in the opinion of the investigator 7. Known contraindications to tissue-engineered allograft 8. Concurrent participation in alternative clinical trial that involves investigational drug or product interfering with wound treatment and/or healing 9. Subject is pregnant or breastfeeding 10. Subject with history of immunosuppressant treatment (systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or topical steroid application to the wound surface for \>2 weeks duration within 30 days prior to randomization; or anticipated use of the above during the course of the study 11. Wound previously treated with CAMPs, tissue engineered, or scaffold materials within 30 days prior to randomization 12. Open wound with active infection 13. Wound depth with visible exposed bone 14. HBOT within 14 days prior to randomization 15. Revascularization surgery on the index wound leg within 30 days of screening phase 16. Index wound suspicious of neoplasm in the opinion of the principal investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Open wound are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    10 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Email: •••••@•••••

Locations

  • MedCentris of Carencro

    COMPLETED

    Lafayette, Louisiana, 70507, United States

  • MedCentris of D'iberville

    COMPLETED

    D'Iberville, Mississippi, 39540, United States

  • MedCentris of Denham Springs

    RECRUITING

    Denham Springs, Louisiana, 70726, United States

  • MedCentris of Hammond

    RECRUITING

    Hammond, Louisiana, 70403, United States

  • MedCentris of Leesville

    RECRUITING

    Leesville, Louisiana, 71146, United States

  • MedCentris of Many

    RECRUITING

    Many, Louisiana, 71449, United States

  • MedCentris of Marksville

    RECRUITING

    Marksville, Louisiana, 71351, United States

  • MedCentris of McComb

    COMPLETED

    McComb, Mississippi, 39648, United States

  • MedCentris of Metairie

    RECRUITING

    Metairie, Louisiana, 70001, United States

  • MedCentris of Minden

    RECRUITING

    Minden, Louisiana, 71055, United States

  • MedCentris of Natchez

    COMPLETED

    Natchez, Mississippi, 39120, United States

  • MedCentris of Slidell

    RECRUITING

    Slidell, Louisiana, 70458, United States

  • MedCentris of Southaven

    RECRUITING

    Southaven, Mississippi, 38671, United States

  • Northeast Podiatry Consultant

    RECRUITING

    Brooklyn, New York, 11234, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.